Capricor Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-40.47	-22.29	-29.02	-20.02	-13.66	Upgrade
Depreciation & Amortization	1.43	1.07	0.53	0.25	0.14	Upgrade
Loss (Gain) From Sale of Assets	0.11	0.01	0.03	0.01	-	Upgrade
Stock-Based Compensation	9.77	7.39	4.46	2.97	1.95	Upgrade
Other Operating Activities	-0.05	-0.02	0.16	-0.27	-	Upgrade
Change in Accounts Receivable	0	-9.82	-0.16	-0.39	0.09	Upgrade
Change in Accounts Payable	1.94	1.33	1.21	0.99	1.83	Upgrade
Change in Unearned Revenue	-12.27	-3.18	27.45	-	-	Upgrade
Change in Other Net Operating Assets	-0.46	-0.08	0.25	-0.34	-0.41	Upgrade
Operating Cash Flow	-40	-25.6	4.92	-16.81	-10.05	Upgrade
Capital Expenditures	-1.54	-2.05	-3.36	-1.2	-0.55	Upgrade
Investment in Securities	-114.64	7.16	-31.71	-	5.99	Upgrade
Investing Cash Flow	-116.18	5.11	-35.07	-1.2	5.44	Upgrade
Long-Term Debt Issued	-	-	-	-	0.32	Upgrade
Net Debt Issued (Repaid)	-	-	-	-	0.32	Upgrade
Issuance of Common Stock	152.77	25.58	4.87	20.23	33.06	Upgrade
Financing Cash Flow	152.77	25.58	4.87	20.23	33.38	Upgrade
Net Cash Flow	-3.41	5.09	-25.28	2.22	28.77	Upgrade
Free Cash Flow	-41.53	-27.64	1.56	-18.01	-10.6	Upgrade
Free Cash Flow Margin	-186.50%	-109.79%	61.02%	-7352.29%	-3417.38%	Upgrade
Free Cash Flow Per Share	-1.18	-1.03	0.06	-0.78	-0.68	Upgrade
Levered Free Cash Flow	-27.78	-10.92	2.34	-10.62	-5.53	Upgrade
Unlevered Free Cash Flow	-27.78	-10.92	2.34	-10.62	-5.53	Upgrade
Change in Net Working Capital	10.83	2.28	-19.27	-0.45	-1.47	Upgrade

Updated Mar 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q